Antibodies tumor cell targeting

Antigen and tumor cell targets Antigen function Naked antibodies Radioisotope-based antibodies Toxin-based antibodies... 

Henning P, Andersson K M, Frykholm K, et al. (2005). Tumor cell targeted gene delivery by adenovirus 5 vectors carrying knobless fibers with antibody-binding domains. Gene Ther. 12 211-224. 

Colloidal gold-labeled (strept)avidin can be used as highly sensitive detection reagents for microscopy techniques (Cubie and Norval, 1989) (Chapter 24). Finally, cytotoxic substances coupled to (strept)avidin can be used to direct cell-killing activity toward a tumor-cell-bound, biotinylated monoclonal antibody (or other targeting molecule) for cancer therapy (Hashimoto et al, 1984) (Chapter 21). 

Reiter, Y., and Fishelson, Z. (1989) Targeting of complement to tumor cells by heteroconjugates composed of antibodies and of the complement component C3b. J. Immunol. 142, 2771. 

McDevitt et al. (2007) reported that multiple copies of tumor-specific monoclonal antibodies were covalently attached to the carbon nanotubes. These tumor-specific antibodies should allow the carbon nanotubes to specifically target tumor cells. This will undoubtedly be beneficial to a patient and will most likely cause reduced side effects. These specific tumor-targeting CNTs may also have reduced... 

Carboxypeptidase G2 (CPG2, glutamate carboxypeptidase, EC 3.4.17.11) is a bacterial enzyme not produced in mammalian cells. It has been used with promising success to target cytotoxic alkylating agents to tumor cells [60][61]. In a series of studies, a CPG2 monoclonal antibody con-... 

Fig. 6.13. Schematic representation of a selective delivery obtained by antibody-directed en-zyme-prodrug therapy (ADEPT). An exogenous enzyme is coupled to a monoclonal antibody (mAb) targeted for tumor cells. In a second step, a prodrug is administered, which, as a selective substrate of the exogenous enzyme, will be selectively activated at the tumor site.

---